cryo-electron-microscopy

Cryo-Electron Microscopy in Neurodegeneration

Introduction

Cryo Electron Microscopy In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Cryo-Electron Microscopy in Neurodegeneration

Introduction

Cryo Electron Microscopy In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Cryo-electron microscopy (cryo-EM) is a structural biology technique that images biological macromolecules in their native, hydrated state at near-atomic resolution by flash-freezing samples in vitreous ice and imaging them with an electron microscope. Since the "resolution revolution" enabled by direct electron detectors and advanced computational methods — recognized with the 2017 Nobel Prize in Chemistry to Jacques Dubochet, Joachim Frank, and Richard Henderson — cryo-EM has transformed the study of [neurodegenerative diseases by revealing the atomic structures of disease-associated protein aggregates, including [amyloid-beta](/proteins/amyloid-beta) fibrils, [tau](/proteins/tau) filaments, and [alpha-synuclein](/proteins/alpha-synuclein) fibrils directly extracted from patient brains. [@fitzpatrick2017]

The ability to determine structures of pathological protein assemblies at 2-4 Å resolution has fundamentally changed our understanding of [protein aggregation](/mechanisms/protein-aggregation) in neurodegeneration. Cryo-EM has revealed that different neurodegenerative diseases are associated with distinct fibril conformations — a concept now known as "structural polymorphism" — with individual fibril structures potentially dictating disease phenotype, progression rate, and regional brain vulnerability. This knowledge is driving rational design of diagnostic agents, therapeutic antibodies, and aggregation inhibitors with unprecedented molecular precision ([Scheres et al., 2020](https://doi.org/10.1038/s41583-020-00375-w)). [@falcon2018]

Key Methodologies

Single-Particle Analysis (SPA)

The most common cryo-EM approach for protein structure determination. Purified protein complexes are vitrified on EM grids, and thousands to millions of 2D projection images are computationally processed to reconstruct a 3D density map: [@zhang2020]

Modern SPA achieves resolutions of 2-3 Å routinely for well-behaved specimens, with some structures reaching below 2 Å, enabling visualization of individual amino acid side chains, water molecules, and drug-binding sites. [@shi2021]

Helical Reconstruction

Amyloid fibrils and other filamentous assemblies have inherent helical symmetry that is exploited by specialized reconstruction algorithms. Helical reconstruction imposes symmetry constraints (rise and twist parameters) during 3D refinement, dramatically increasing the effective number of asymmetric units averaged and enabling high-resolution structures from relatively heterogeneous fibril samples. [@schweighauser2020]

This approach, pioneered by the group of Michel Goedert and Sjors Scheres at the MRC Laboratory of Molecular Biology ([University of Cambridge](/institutions/cam-mrc-lmb), has been transformative for determining structures of disease-associated amyloid fibrils extracted directly from patient brain tissue ([Fitzpatrick et al., 2017](https://doi.org/10.1038/nature23002)). [@yang2023]

Cryo-Electron Tomography (Cryo-ET)

Cryo-ET images biological samples from multiple tilt angles, generating 3D tomographic reconstructions that reveal structures in situ — within cells, tissues, or organelles. Combined with subtomogram averaging, cryo-ET can achieve ~4-8 Å resolution on repeated structural motifs within cellular environments. [@arseni2022]

For neurodegeneration research, cryo-ET enables: [@falcon2019]

• Visualization of amyloid fibrils within [neurons](/entities/neurons) and extracellular space
• Imaging of [tau](/proteins/tau) filaments] in their native cellular context
• Structural analysis of [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) and lysosomal machinery surrounding aggregates
• Direct observation of mitochondrial structural changes in disease

Micro-Electron Diffraction (MicroED)

MicroED uses electron diffraction from nanocrystals of proteins or peptides to determine atomic structures. For neurodegeneration research, MicroED has revealed the structures of short amyloidogenic peptide segments (e.g., VQIVYK from tau, KLVFFA from [amyloid-beta](/proteins/amyloid-beta) that form the core of pathological fibrils, providing insight into the molecular basis of cross-seeding between different amyloid proteins. [@yan2025]

Landmark Structures in Neurodegeneration

Tau Filaments

Alzheimer's Disease: The first cryo-EM structures of tau filaments from [Alzheimer's disease](/diseases/alzheimers-disease) brain, determined at 3.4-3.5 Å resolution by Fitzpatrick et al. (2017), revealed that paired helical filaments (PHF) and straight filaments (SF) are composed of two identical protofilaments comprising tau residues 306-378 (the core of repeats R3 and R4), arranged in a C-shaped fold. The two filament types differ only in the inter-protofilament interface. These structures established the paradigm that [tauopathies](/mechanisms/tauopathies) are defined by distinct tau fibril folds ([Fitzpatrick et al., 2017](https://doi.org/10.1038/nature23002)). [@goedert2017]

Pick's disease: [Pick disease](/diseases/pick-disease) tau filaments revealed a completely different fold involving only 3R tau isoforms (residues 254-378), demonstrating that different [tauopathies](/mechanisms/tauopathies) feature structurally distinct tau assemblies.

Progressive Supranuclear Palsy: [PSP](/diseases/psp) tau filaments contain a fold involving 4R tau isoforms that is distinct from both AD and Pick's folds, with the R1-R4 domains arranged in a three-layered beta-helix structure.

Corticobasal Degeneration: [CBD](/diseases/corticobasal-degeneration) tau filaments share some structural features with PSP but adopt a unique four-layered fold, demonstrating that even closely related clinical [tauopathies](/mechanisms/tauopathies) have distinguishable molecular architectures.

Chronic traumatic encephalopathy: [CTE](/mechanisms/cte) tau filaments adopt the AD fold but with a distinctive additional beta-strand (residues 7-20 from the N-terminus), establishing CTE as a structurally unique tauopathy despite clinical overlap with AD.

Primary age-related tauopathy: PART tau filaments were found to be structurally identical to AD tau filaments, supporting the hypothesis that PART represents a forme fruste of AD.

alpha-synuclein Filaments

Parkinson's Disease / Dementia with Lewy bodies: Cryo-EM structures of [alpha-synuclein](/proteins/alpha-synuclein) filaments from [Parkinson's disease](/diseases/parkinsons-disease) and [Lewy body dementia](/diseases/lewy-body-dementia) brains revealed the "Lewy fold" — a single protofilament structure spanning residues ~37-99 that is markedly different from the structures of recombinant [alpha-synuclein](/proteins/alpha-synuclein) fibrils or those from [multiple system atrophy](/diseases/multiple-system-atrophy).

Multiple System Atrophy: [MSA](/diseases/msa-genetic-variants) [alpha-synuclein](/proteins/alpha-synuclein) filaments were found to adopt a two-protofilament structure completely different from the Lewy fold, establishing MSA as a structurally distinct synucleinopathy. A 2025 study expanded the spectrum of known MSA filament types to include a fourth subtype (Type I2), further demonstrating the structural heterogeneity of MSA ([Yan et al., 2025](https://doi.org/10.1002/1873-3468.15048)).

These structural differences between Lewy body diseases and MSA explain why [alpha-synuclein](/proteins/alpha-synuclein) strains propagate differently and produce distinct clinical phenotypes — a key insight for understanding [prion-like spreading](/mechanisms/prion-like-spreading) in [synucleinopathies](/mechanisms/synucleinopathies).

Amyloid-Beta Fibrils

Cryo-EM structures of [amyloid-beta](/proteins/amyloid-beta) fibrils from [Alzheimer's disease](/diseases/alzheimers-disease) brain revealed:

• Type I and Type II fibrils: Two major [Aβ](1-42) fibril polymorphs with distinct cross-beta spine structures
• Familial AD variants: Fibrils from patients with [PSEN1](/genes/psen1) and [APP](/entities/app-protein) mutations show altered fibril structures compared to sporadic AD, potentially explaining different disease phenotypes
• Cerebral amyloid angiopathy: CAA [Aβ](/proteins/amyloid-beta-protein) fibrils have different structures from parenchymal plaque fibrils, even within the same patient, suggesting distinct aggregation pathways in blood vessels versus brain parenchyma

TDP-43 and FUS

Cryo-EM structures of [TDP-43](/proteins/tdp-43) filaments from [ALS](/diseases/als) and FTLD brains revealed the amyloid core of [TDP-43](/proteins/tdp-43) pathology, providing atomic-level insight into [TDP-43](/proteins/tdp-43) proteinopathy]. Different FTLD-TDP subtypes (Types A-E) show distinct [TDP-43](/proteins/tdp-43) fibril structures, paralleling the tauopathy paradigm.

Huntingtin

While full-length [huntingtin](/proteins/huntingtin) aggregates remain challenging due to structural heterogeneity, cryo-EM of polyglutamine (polyQ) segments has revealed the steric zipper and cross-beta architecture of [trinucleotide repeat expansion](/mechanisms/trinucleotide-repeat-expansion) aggregates relevant to [Huntington's disease](/mechanisms/huntington-pathway).

Impact on Disease Understanding

Structural Basis of Disease Classification

Cryo-EM has established that neurodegenerative diseases can be classified by their characteristic fibril folds:

| Disease | Protein | Fold | Protofilaments |
|---------|---------|------|----------------|
| Alzheimer's Disease | [Tau](/proteins/tau) (3R+4R) | C-shaped (R3-R4) | 2 |
| Pick's disease | [Tau](/proteins/tau) (3R) | Elongated (R1-R3-R4) | 2 |
| PSP | Tau (4R) | Three-layered | 1 |
| CBD | Tau (4R) | Four-layered | 2 |
| CTE | Tau (3R+4R) | AD-like + N-terminal | 2 |
| PD/DLB | α-Synuclein | Lewy fold | 1 |
| MSA | α-Synuclein | Two-protofilament | 2 |
| FTLD-TDP Type A | [TDP-43](/proteins/tdp-43) | Distinct per subtype | Variable |

Strain Hypothesis

Cryo-EM structures have provided the molecular basis for the "strain" hypothesis in neurodegeneration: different fibril conformations (strains) of the same protein produce distinct diseases, analogous to prion strains in [prion diseases](/diseases/prion-diseases). This has profound implications for understanding [prion-like spreading](/mechanisms/prion-like-spreading) and developing strain-specific diagnostics.

Drug Design and Therapeutic Implications

High-resolution fibril structures enable:

• Structure-based design of aggregation inhibitors that target specific fibril-forming interfaces
• Rational design of therapeutic antibodies ([lecanemab](/therapeutics/lecanemab), donanemab) targeting specific conformational epitopes
• PET tracer development for diagnostic imaging agents that bind specific fibril conformations
• Seeding assay optimization for ultrasensitive diagnostic tests based on real-time quaking-induced conversion (RT-QuIC)

Technical Advances and Current State

Resolution Improvements

The field has progressed dramatically:

• 2017: First tau structures at 3.4 Å from patient brain tissue
• 2020: Sub-3 Å structures of multiple disease fibrils
• 2024: α-Synuclein fibrils at 2.04 Å resolution, enabling visualization of individual water molecules and small molecule binding sites

Sample Preparation Advances

• Sarkosyl-insoluble fraction extraction: Standardized protocols for isolating disease-associated filaments from postmortem brain tissue
• Immunodepletion: Removal of non-target aggregates for cleaner preparations
• Cryo-FIB milling: Focused ion beam milling of vitrified cells to create thin lamellae for cryo-ET of aggregates in cellular context

Computational Methods

• AlphaFold and deep learning: Integration of AI-predicted structures with cryo-EM density maps accelerates model building
• CryoDRGN: Deep learning-based heterogeneity analysis reveals conformational landscapes of fibril assemblies
• Automated processing: End-to-end pipelines (cryoSPARC Live, RELION 5) enable real-time data processing during collection

Challenges and Limitations

• Sample heterogeneity: Patient brain extracts contain mixtures of fibril types, modification states, and aggregation intermediates that can limit achievable resolution
• Post-translational modifications: Many disease-associated modifications (phosphorylation, ubiquitination, acetylation) are difficult to resolve unless occupancy is high
• Oligomeric intermediates: Small, transient oligomeric species implicated in neurotoxicity are challenging to capture by cryo-EM due to their dynamic nature and small size
• Functional context: Cryo-EM of extracted fibrils reveals the end-stage structure but not the dynamic aggregation process; complementary biophysical methods are needed

Future Directions

In Situ Structural Biology

Cryo-ET combined with cryo-FIB milling will enable visualization of amyloid fibrils, tau tangles, and [Lewy bodies](/mechanisms/alpha-synuclein) within intact [neurons](/entities/neurons) at near-atomic resolution, revealing how aggregates interact with cellular organelles and membranes.

Time-Resolved Cryo-EM

Rapid mixing and flash-freezing devices enable capture of aggregation intermediates at defined time points, potentially revealing the structural transitions during fibril nucleation and elongation that are targets for therapeutic intervention.

Correlative Light and Electron Microscopy (CLEM)

Combining fluorescence microscopy with cryo-EM allows identification of specific cellular structures (e.g., fluorescently labeled aggregates) before high-resolution cryo-EM/ET imaging, bridging the scale gap between light and electron microscopy.

Clinical Diagnostics

Cryo-EM-defined fibril structures inform development of conformation-specific biomarkers and seed amplification assays for diagnostic classification of [tauopathies](/mechanisms/tauopathies), [synucleinopathies](/mechanisms/synucleinopathies), and [TDP-43](/proteins/tdp-43) proteinopathies from patient biofluids.

See Also

• [Huntingtin (HTT)](https://www.uniprot.org/uniprot/P42857)

Background

The study of Cryo Electron Microscopy In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving cryo-electron-microscopy discovered through SciDEX knowledge graph analysis: